文献速递免疫规划

HIV-1疫苗7年后加强免疫:AIDSVAX蛋白增强可拓宽并提高抗体应答

AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
PubMed 文献 · Vaccine · 2021-07-03

HVTN 114试验对曾接种MVA/HIV62B或DNA/MVA/HIV62B的27名参与者,在7年休息期后给予不同加强方案。结果显示所有方案安全耐受,AIDSVAX(无论是否联合MVA)可提高gp120和V1V2结合抗体的幅度与广度,MVA(无论是否联合AIDSVAX)可提高gp140/gp41抗体及CD4+T细胞应答。

要点

  • 7年后仍可检测到结合抗体和CD4+T细胞应答。
  • AIDSVAX加强可拓宽并提高gp120/V1V2抗体应答。
  • MVA加强可提高gp140/gp41抗体及Env/Gag CD4+T细胞应答。

核心结论

  • 晚期加强接种AIDSVAX(单用或联合MVA)可拓宽结合抗体应答并提高T细胞应答,即使距原始MVA/HIV62B(含或不含DNA priming)接种多年。

研究设计与样本

  • HVTN 114疫苗试验纳入27名曾参加HVTN 205的参与者,随机分入五组接受不同加强方案,加强剂次为第0和4个月,随访安全性及免疫原性10个月。

主要发现

  • 所有加强方案均安全且耐受良好。
  • 加强前(即HVTN 205接种后7年)仍可观察到结合抗体和CD4+T细胞应答。
  • 晚期AIDSVAX加强(含或不含MVA)对gp120和V1V2表位产生高结合抗体应答,幅度和广度较HVTN 205时增加。
  • 晚期MVA加强(含或不含AIDSVAX)导致gp140和gp41抗体应答增加,且对Env和Gag的CD4+T细胞应答更高。

临床怎么用

  • 对既往接种过MVA/HIV62B(含或不含DNA priming)者,多年后采用AIDSVAX蛋白加强可能拓宽HIV-1包膜特异性抗体应答。

局限性

  • 样本量小(共27人),分组后每组4-7人,结果基于汇总分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eliciting durable humoral immunity with sufficient breadth and magnitude is important for HIV-1 vaccine design. The HVTN 114 vaccine trial evaluated different boost regimens administered after a 7-year rest period in participants previously enrolled in HVTN 205, who received either three MVA/HIV62B (MMM) or two DNA and two MVA/HIV62B (DDMM) injections; both vaccines expressed multiple HIV-1 antigens in non-infectious virus-like-particles. The primary objective of HVTN 114 was to assess the impact of a heterologous gp120 protein AIDSVAX B/E boost on the magnitude, breadth and durability of vaccine-induced immune responses. METHODS: We enrolled 27 participants from HVTN 205 into five groups. Eight participants who previously received MMM were randomized and boosted with either MVA/HIV62B alone (T1; n = 4) or MVA/HIV62B and AIDSVAX B/E (T2; n = 4). Nineteen participants who received DDMM were randomized and boosted with MVA/HIV62B alone (T3; n = 6), MVA/HIV62B and AIDSVAX B/E (T4; n = 6), or AIDSVAX B/E alone (T5; n = 7). Boosts were at months 0 and 4. Participants were followed for safety and immunogenicity for 10 months and were pooled for analysis based on the regimen: MVA-only (T1 + T3), MVA + AIDSVAX (T2 + T4), and AIDSVAX-only (T5). RESULTS: All regimens were safe and well-tolerated. Prior to the boost vaccination, binding antibody and CD4+T-cell responses were observed 7 years after HVTN 205 vaccinations. Late boosting with AIDSVAX, with or without MVA, resulted in high binding antibody responses to gp120 and V1V2 epitopes, with increased magnitude and breadth compared to those observed in HVTN 205. Late boosting with MVA, with or without AIDSVAX, resulted in increased gp140 and gp41 antibody responses and higher CD4+T-cell responses to Env and Gag. CONCLUSIONS: Late boosting with AIDSVAX, alone or in combination with MVA, can broaden binding antibody responses and increase T-cell responses even years following the original MVA/HIV62B with or without DNA-priming vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Huang Y, Seaton KE, Casapia M, et al. AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. Vaccine. 2021. PMID: 34229888. doi:10.1016/j.vaccine.2021.06.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。